SCHEMBL25344401

SCHEMBL25344401

COc1cc(F)c(F)cc1-n1ncc2c(Cl)ncnc21

nearest known ligand 0.47

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
SLC2A1 P11166 10/20 0.47
SLC2A3 P11169 9/20 0.47
SLC2A2 P11168 5/20 0.47
MAPT P10636 5/20 0.43
PIP4K2A P48426 6/20 0.42
LMNA P02545 2/20 0.41
TP53 P04637 2/20 0.41
KDM4E B2RXH2 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
PIK3CG P48736 1/20 0.40
PIP4K2C Q8TBX8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25344741 0.85 SLC2A1 (0.56) SLC2A1SLC2A3SLC2A2MAPTPIP4K2A
SCHEMBL25344174 0.82 MAPT (0.58) SLC2A1SLC2A3SLC2A2MAPTPIP4K2A
SCHEMBL25343885 0.82 PIP4K2A (0.54) SLC2A1SLC2A3SLC2A2MAPTPIP4K2A
SCHEMBL25344682 0.80 SLC2A1 (0.42) SLC2A1SLC2A3SLC2A2MAPTPIP4K2A
SCHEMBL838951 0.79 SLC2A1 (0.65) SLC2A1SLC2A3SLC2A2MAPTLMNA
SCHEMBL25341841 0.78 SLC2A1 (0.42) SLC2A1SLC2A3SLC2A2MAPTPIP4K2A
SCHEMBL25343612 0.77 SLC2A1 (0.48) SLC2A1SLC2A3SLC2A2MAPTPIP4K2A
SCHEMBL12414250 0.75 RAB9A (0.53) MAPTPIP4K2ALMNATP53KDM4E
SCHEMBL30568614 0.75 HSP90AA1 (0.42) SLC2A1SLC2A3SLC2A2MAPTPIP4K2A
SCHEMBL25344672 0.75 SLC2A1 (0.45) SLC2A1SLC2A3SLC2A2MAPTPIP4K2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4472739-A1 IMIDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. Hoffmann-La Roche AG (CH) 2024-12-11 EP disclosed
WO-2023148129-A1 IMIDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. HOFFMANN-LA ROCHE AG (CH) 2023-08-10 WO disclosed